» Articles » PMID: 23104894

Association Between VEGF Splice Isoforms and Progression-free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2012 Oct 30
PMID 23104894
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Bevacizumab improves survival for patients with metastatic colorectal cancer with chemotherapy, but no proven predictive markers exist. The VEGF-A splice form, VEGF(165)b, anti-angiogenic in animal models, binds bevacizumab. We tested the hypothesis that prolonged progression-free survival (PFS) would occur only in patients with low relative VEGF(165)b levels treated with bevacizumab.

Experimental Design: Blinded tumor samples from the phase III trial of FOLFOX4 ± bevacizumab were assessed for VEGF(165)b and VEGF(total) by immunohistochemistry and scored relative to normal tissue. A predictive index (PI) was derived from the ratio of VEGF(165)b:VEGF(total) for 44 samples from patients treated with FOLFOX + bevacizumab (arm A) and 53 samples from patients treated with FOLFOX4 (arm B), and PFS, and overall survival (OS) analyzed on the basis of PI relative to median ratio.

Results: Unadjusted analysis of PFS showed significantly better outcome for individuals with VEGF(165)b:VEGF(total) ratio scores below median treated with FOLFOX4 + bevacizumab compared with FOLFOX4 alone (median, 8.0 vs. 5.2 months; P < 0.02), but no effect of bevacizumab on PFS in patients with VEGF(165)b:VEGF(total) ratio >median (5.9 vs. 6.3 months). These findings held after adjustment for other clinical and demographic features. OS was increased in arm A (median, 13.6 months) compared with arm B (10.6 months) in the low VEGF(165)b group, but this did not reach statistical significance. There was no difference in the high VEGF(165)b:VEGF(total) group between FOLFOX + bevacizumab (10.8 months) and FOLFOX alone (11.3 months).

Conclusion: Low VEGF(165)b:VEGF(total) ratio may be a predictive marker for bevacizumab in metastatic colorectal cancer, and individuals with high relative levels may not benefit.

Citing Articles

The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF and downregulating VEGF.

Quan B, Li Z, Yang H, Li S, Yan X, Wang Y Heliyon. 2023; 9(8):e18706.

PMID: 37554848 PMC: 10405001. DOI: 10.1016/j.heliyon.2023.e18706.


Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced non-small-cell lung cancer.

Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T Transl Lung Cancer Res. 2023; 12(6):1167-1184.

PMID: 37425411 PMC: 10326775. DOI: 10.21037/tlcr-22-632.


A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X Mol Oncol. 2023; 17(7):1379-1401.

PMID: 36810959 PMC: 10323879. DOI: 10.1002/1878-0261.13401.


Impaired VEGF-A-Mediated Neurovascular Crosstalk Induced by SARS-CoV-2 Spike Protein: A Potential Hypothesis Explaining Long COVID-19 Symptoms and COVID-19 Vaccine Side Effects?.

Talotta R Microorganisms. 2022; 10(12).

PMID: 36557705 PMC: 9784975. DOI: 10.3390/microorganisms10122452.


Comprehensive Analysis of Splicing Factor and Alternative Splicing Event to Construct Subtype-Specific Prognosis-Predicting Models for Breast Cancer.

Zhang H, Han B, Han X, Zhu Y, Liu H, Wang Z Front Genet. 2021; 12:736423.

PMID: 34630526 PMC: 8497829. DOI: 10.3389/fgene.2021.736423.


References
1.
Qiu Y, Bevan H, Weeraperuma S, Wratting D, Murphy D, Neal C . Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J. 2007; 22(4):1104-12. DOI: 10.1096/fj.07-9718com. View

2.
Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J . The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008; 98(7):1250-7. PMC: 2359649. DOI: 10.1038/sj.bjc.6604309. View

3.
Rennel E, Varey A, Churchill A, Wheatley E, Stewart L, Mather S . VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer. 2009; 101(7):1183-93. PMC: 2768092. DOI: 10.1038/sj.bjc.6605249. View

4.
Rennel E, Hamdollah-Zadeh M, Wheatley E, Magnussen A, Schuler Y, Kelly S . Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer. 2008; 44(13):1883-94. PMC: 2565644. DOI: 10.1016/j.ejca.2008.05.027. View

5.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View